Metabolic Characterization of Space Occupying Lesions of the Brain
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInsel Gruppe AG, University Hospital Bern
About this trial
High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not.
The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas.
A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.
Eligibility criteria
Qualifiers
Healthy people who are able to lie in the MR scanner for one hour;
Patients with suspected mass in the brain
Written informed consent
Disqualifiers
Persons under the age of 18
Persons who are mentally unable to choose to participate
Pregnant women
Patients with oncological findings or neurodegenerative findings in the past
Trial design
Treatments tested in this trial
- MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
Treatment groups
55 Participants
are divided into 4 treatment groupsSponsors and collaborators
Insel Gruppe AG, University Hospital Bern
Lead sponsor
Swiss National Science Foundation
Collaborator
Source ClinicalTrials.gov